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Bone morphogenetic proteins (BMP) are multi-functional growth factors to promote bone
healing with the proposal of less morbidity compared to the usual methods of bone graft
harvest. Pseudoarthrosis occur when the fusion attempt fails, a solid fusion is not achieved,
or  there is motion across the segment leading to it, and it can be clinically symptomatic as
pain,  deformity, neurocompression, or hardware failure. BMPs are used at spinal fusion as
a  tool for the treatment of degenerative, traumatic, neoplastic and infectious conditions of
the  spine. This review shows that the use of BMPS is effective and secure when compared
with  iliac crest bone graft (ICGB); however, depending of the location of usage (cervical spine,
lumbar spine or sacrum) and the medical status of the patient (presence of comorbidities,
tobacco usage), it is more likely to exhibit complications. Therefore, the use of these proteins
must  be an informed decision of patient and physician preferences.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
O  uso  de  proteínas  morfogenéticas  ósseas  (BMP)  e  pseudoartroses,  uma
revisão  de  literatura
alavras-chave:
roteínas morfogenéticas ósseas 2
r  e  s  u  m  o
Proteínas morfogenéticas do osso (Bone morphogenetic proteins [BMP]) são fatores de
crescimento multifuncionais que promovem cicatrizac¸ão óssea, propondo menos comor-
roteína morfogenética óssea 7 bidades comparado aos métodos usuais de colheita de enxerto ósseo. Pseudoartroses
entativa de fusão óssea falha, uma fusão sólida não é atingida ouseudoartrose ocorrem quando a tPlease cite this article in press as: Oliveira OR, et al. The use of bone morphogenetic proteins (BMP) and pseudarthrosis, a literature review. Rev
Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.03.005
quando há movimentac¸ão do segmento que leva à pseudoartrose, que pode ser clinicamente
sintomática com dor, deformidade, neurocompressão ou falha na colocac¸ão de material
de  síntese. As BMPs são usadas em fusão colunar como ferramenta para o tratamento de
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trauma degenerativo, condic¸ões neoplásicas e infecciosas da coluna. A presente revisão da
literatura mostra que o uso de BMPs é efetivo e seguro quando comparado com enxerto
ósseo ilíaco. No entanto, a depender do local de uso (coluna cervical ou lombar ou sacro)
e  do estado médico do paciente (presenc¸a de comorbidades, tabagismo) é mais propício
o  aparecimento de complicac¸ões. Portanto, o uso dessas proteínas deve ser decidido após
uma decisão conjunta de preferências médicas e do paciente.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://Introduction
Bone morphogenetic proteins (BMP) are multi-functional
growth factors that belong to the transforming growth fac-
tor beta (TGF-beta) superfamily, they were introduced in the
medical scenario to promote bone healing with the proposal
of less morbidity compared to the usual methods of bone graft
harvest; it is the only bone inducer with level I of clinical evi-
dence. The Food and Drug Administration (FDA) approved its
use in July of 2002 for anterior approaches of lumbar spine
fusion procedures.
The spinal fusion is a tool for the treatment of degenerative,
traumatic, neoplastic and infectious conditions of the spine,
it can be achieved with interbody fusion, posterior or pos-
terolateral fusion and circumferencial fusion. The most used
examples of BMP’s are recombinant human BMP-2 (rhBMP-2
is approved for anterior lumbar interbody fusions – ALIF) and
recombinant human BMP-7 (rhBMP-7 has received a human-
itarian device exemption for revision posterolateral lumbar
fusion operation).
Implants containing BMP’s are promising to its safety and it
is as effective as iliac crest bone graft (ICBG). Adopting the use
of it brings high costs and it has safety concerns with reported
complication speciﬁcs to its use, including osteolysis, ectopic
bone formation, radiculitis, cervical soft tissue swelling and
pseudoarthrosis.
Nowadays the greatest use of BMP  is for off label treatments
as an adjunt to allograft or autograft bone – often replac-
ing the use of ICBG in mandibular reconstruction, unspeciﬁc
oral and maxillofacial facial surgeries, cervical spine fusion,
pseudoarthrosis fusion. But it is still in the need of further
investigation related to its collateral effects.
Pseudoarthrosis occur when the fusion attempt fails,
a solid fusion is not achieved, or there is motion across
the segment leading to it, and it can be clinically symp-
tomatic as pain, deformity, neurocompression or hardware
failure. There are two types: hypertrophic/hypercascular and
atrophic/avascular, the last one is applicable osteoinductive
treatment with BMP.  This review intends to correlate and clar-
ify the use of BMP’s and its bias on pseudoarthrosis, when it
is a correction or cause factor.
MethodsPlease cite this article in press as: Oliveira OR, et al. The use of bone morp
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A qualitative systematic review of articles about the use of
Bone Morphogenetic Protein in Pseudarthrosis was developed
on a basis of preselected data. It was performed a search ofcreativecommons.org/licenses/by-nc-nd/4.0/).
literature from the online database BVS and SCOPUS from Jan-
uary 2006 to November 2015. The search was focused from the
following terms: (1) ‘Pseudarthrosis’ {Medical Subject Head-
ings} [MeSH term]; and (2) ‘Bone Morphogenetic Proteins’
{Medical Subject Headings}  [MeSH term], these terms were
chosen to deﬁne our central matter of the paper and all articles
were evaluated with rigor to proper sampling.
The analysis of the articles follows predeﬁned eligibility
criteria. We  adopt the following inclusion criteria: (1) origi-
nal articles with full text online access; (2) From the relevant
source titles: ‘Spine’, ‘Injury’, ‘Spine Journal’, ‘Journal of Bone
and Joint Surgeries Series A’, ‘Journal of Neurosurgery Spine’
and ‘Journal of Orthopaedic Research’; (3) Observational,
experimental or quasi-experimental studies; (4) Writings in
English only; (5) Studies which focus on the use of BMP  in
pseudarthrosis.
Exclusion criteria were: (1) other projects, such as case
reports, case series, literature review and comments, (2) The
non-original studies, including editorials, comments, pref-
aces, brief comments and letter to the editor; (3) Productions
that did not accomplish the proposed theme; and (4) the arti-
cles in which the objective of the study did not matched the
theme purposed by the systematic review in question.
We  found applicable 85 articles that, when screened,
resulted in 24 articles that met  the criteria of evidence and
were included in this review (Table 1).
Discussion
BMPs were developed with the goal of improving clinical out-
comes through the promotion of bony healing and reducing
morbidity from ICBG (still considered ‘gold standard’ to multi-
level spine fusion).1,2 Spinal fusion procedure is indicated for
a variety of pathological states including spinal instability sec-
ondary to trauma, infection, or neoplasm as well as intractable
axial pain caused by degenerative disorders.3 Achieving fusion
is difﬁcult because of poor local bone quality and long fusions
have a negative variable that inhibits a solid fusion, and the
BMP  is been researched as a potential solution for this prob-
lem.
Bone morphogenetic and osteogenetic proteins are mul-
tifunctional growth factors that belong to the transforming
growth factor-b superfamily. Although osteogenetic proteins
are primarily considered osteogenic factors, further inves-
tigations have shown that these proteins are also essentialhogenetic proteins (BMP) and pseudarthrosis, a literature review. Rev
for embryogenesis and organogenesis, and that they have
pleiotropic roles in cell growth, differentiation, migration,
and apoptosis. The most used examples of BMP’s are rhBMP-2
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Table 1 – The use of bone morphogenetic proteins and pseudarthrosis review.
n.◦ Authors and Year Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
1 Dagostino PR;
Whitmore RG;
Smith GA;
Maltenfort MG;
Ratliff JK. 2014
Impact of bone
morphogenetic
proteins on frequency
of revision surgery, use
of autograft bone, and
total hospital charges
in surgery for lumbar
degenerative disease:
review of the
Nationwide Inpatient
Sample from 2002 to
2008.
Spine J Study design: Nationwide Inpatient
Sample (NIS) retrospective cohort
assessment of 46,452 patients from
2002 to 2008. Patient sample: All
patients who  underwent lumbar
arthrodesis procedures for
degenerative spinal disease.
Outcome measures: Use of BMP,
revision surgery status as a
percentage of total procedures, and
autograft harvest in lumbar fusion
procedures completed for
degenerative diagnoses. Methods:
Demographic and
geographic/practice data, hospital
charges, and length of stay of all
NIS  patients with thoracolumbar
and lumbosacral procedure codes
for degenerative spinal diagnoses
were recorded. Codes for autograft
harvest, use of BMP,  and revision
surgery were included in
multivariable regression analysis.
The assessment found 46,452
patients from 2002 to 2008
undergoing thoracolumbar or lumbar
arthrodesis procedures for
degenerative disease. Assuming a
representative sample, this cohort
models more  than 200,000 US
patients. There was steady growth in
lumbar spine fusion and in the use of
BMP.  The use of BMP  increased from
2002 to 2008 (odds ratio [OR], 1.50;
95% conﬁdence interval [CI],
1.48–1.52). Revision procedures
decreased over the study period (OR,
0.94; 95% CI, 0.91–0.96). The use of
autograft decreased substantially
after introduction of BMP  but then
returned to baseline levels; there was
no net change in autograft use from
2002 to 2008. The use of BMP
correlated with signiﬁcant increases
in hospital charges ($13,362.39;
standard deviation ± 596.28,
p < .00001). The use of BMP  in
degenerative thoracolumbar
procedures potentially added more
than $900 million to hospital charges
from 2002 to 2008.
There was an overall
decrease in rates of
revision fusion
procedures from
2002 to 2008.
Introduction of BMP
did not correlate
with decrease in use
of autograft bone
harvest. Use of BMP
correlated with
substantial increase
in hospital charges.
The small decrease
in revision surgeries
recorded, combined
with lack of
signiﬁcant change in
autograft harvest
rates, may question
the ﬁnancial
justiﬁcation for the
use of BMP.
Included PubMed/
BVS
2 Crandall DG;
Revella J;
Patterson J; Huish
E; Chang M;
McLemore R.2013
Transforaminal
lumbar interbody
fusion with rhBMP-2 in
spinal deformity,
spondylolisthesis, and
degenerative
disease–part 2: BMP
dosage-related
complications and
long-term outcomes in
509 patients.
Spine
(Phila Pa
1976)
TLIF with rhBMP-2 was performed
at 872 discs in 509 consecutive
adults who  underwent open
posterior instrumented fusion and
had minimum 2-year follow-up;
diagnoses included degenerative
disease (179), spondylolisthesis
(207), deformity (123). Patient age
averaged 61 years: 12% were
smokers and 41% had revision
surgery. TLIF was performed at 1.7
levels: single level: 229, 2 levels:
201, 3 levels: 74, 4 levels: 5. Local
autograft was used for backﬁll
around and behind each
rectangular cage. Varying doses of
interbody BMP  were used at an
average 7.3 mg per disk (range:
2–12 mg  per disk).
At 5 years average follow-up, 8
patients developed pseudoarthrosis
at levels of TLIF (8 of 872 discs,
0.92%). Seroma (0.4%) and ectopic
bone growth (0.6%) were too
infrequent to be associated with a
particular BMP  dose. Deep  infection
was 2.6% overall (1.7% of the
degenerative group). Symptomatic
osteolysis or cage subsidence did not
occur. Signiﬁcant long-term
improvement was noted in clinical
and functional outcomes compared
with preoperation.
Five-year follow-up
after TLIF with BMP,
independent of
industry, conﬁrms
effective arthrodesis
in short and  long
fusions, both
primary and
revision. Most
complications
occurred in
deformity patients.
BMP-related
complications
(seroma, ectopic
bone) were rare.
Level of evidence: 3.
Included PubMed
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Table 1 – (Continued)
n.◦ Authors
and  Year
Title  Journal  Sample  Main  ﬁndings  Conclusion  Reason  for
inclusion/
exclusion
Database
3  Crandall  DG;
Revella  J;
Patterson  J;
Huish  E;  Chang
M;  McLemore  R.
2013
Transforaminal  lumbar
interbody  fusion  with
rhBMP-2  in  spinal  deformity,
spondylolisthesis,  and
degenerative  disease–part  1:
Large  series  diagnosis
related  outcomes  and
complications  with  2-  to
9-year  follow-up.
Spine
(Phila  Pa
1976)
A  total  of  509  consecutive  adults
underwent  open  posterior
instrumented  fusion,
augmented  with  TLIF  at  872
discs  using  a  cage  and  rhBMP-2,
with  minimum  2-year
follow-up.  Cohort  diagnoses
included  179  degenerative,  207
spondylolisthesis,  and  123
deformity  patients.  Patient  age
averaged  61  years,  207  had
undergone  prior  decompression
or fusion  surgery.  All  patients
underwent  posterior
instrumented  fusion  and
pedicle  screw  instrumentation
at  average  3.6  levels  (range,
1–16);  all  patients  had  TLIF  1.7
levels  (range,  1–4  levels)  with
BMP  and  autograft,  stabilized
with  an  interbody  cage.
At  average  59  months  follow-up,  12
patients  developed  pseudoarthrosis,
8  at  TLIF  levels  (8/872  discs,  0.92%)
most  commonly  at  L5-S1  (6/8).
Signiﬁcant  clinical  improvement  was
noted  in  patients  with  deformity,
spondylolisthesis,  and  degenerative
disease  undergoing  primary  and
revision  surgery.  Overall,  visual
analog  scale  preoperative  score  was
6.6,  at  1  year  3.8,  at  2  years  3.5
(p  <  0.001)  and  the  preoperative  ODI
was  50.9,  at  1  year  36.1,  and  at  2  years
35.0  (p  <  0  0.001).  Pain  medication
requirements  also  declined.
The  efﬁcacy  of  TLIF  with  BMP
is  supported  in  this  large
series  with  long-term
follow-up,  independent  of
industry.  Reliable  fusion  and
improved  outcomes  can  be
expected  in  adults
undergoing  TLIF  for
deformity,  spondylolisthesis,
and  degenerative  disease.
Most  complications  occurred
in  patients  with  deformity.
Level  of  evidence:  3.
Included  PubMed
4  Shimer  AL;
Oner  FC;
Vaccaro  AR.
2009
Spinal  reconstruction  and
bone  morphogenetic
proteins:  open  questions.
Injury  Included  PubMed
5  Klimo  P;  Peelle
MW.  2009
Use  of  polyetheretherketone
spacer  and  recombinant
human  bone  morphogenetic
protein-2  in  the  cervical
spine:  a  radiographic
analysis.
Spine  J  All  patients  underwent  detailed
postoperative  radiologic
analysis  using  a  computed
tomography  (CT)  scan  obtained
at least  6  months
postoperatively  and  plain  X-rays
obtained  at  regular  intervals.
Twenty-two  patients  had  38  levels
fused  using  PEEK  and  varying  doses
of  rhBMP-2.  No  anterior  cervical
swelling  requiring  additional
procedures  or  longer  than  anticipated
hospital  stays  occurred.
Pseudoarthrosis,  shown  as  a
horizontal  radiolucent  ﬁssure
through  the  midportion  of  the  PEEK
cage  on  CT,  occurred  in  four  patients.
Excessive  bone  growth  into  the  spinal
canal  or  foramina  occurred  in  26
(68%)  patients  but  did  not  result  in
neurologic  sequelae.  Cystic  regions  in
the  core  of  the  PEEK  spacer  were  seen
in most  patients,  with  15  levels  (39%)
having  cysts  measuring  3  mm  or
greater.  Moderate  or  severe  osteolysis
of  the  end  plates  occurred  in  57%  of
levels,  and  this  led  to  subsidence  of
the  construct  and  loss  of  some  of  the
segmental  sagittal  alignment  (i.e.,
lordosis)  that  had  been  achieved  with
surgery.
The  unlimited  supply  of  PEEK
spacers  and  rhBMP-2  and
their  ease  of  use  make  them
attractive  platforms  to
achieve  fusion.  This  study  has
demonstrated  that  the  fusion
process  using  rhBMP-2  is  a
dynamic  one,  with  osteolysis
dominating  the  initial  phase,
leading  to  end-plate
resorption  and  consequently
loss  of  some  of  the  disk  space
height  and  sagittal  alignment
that  was  achieved  with
surgery.  There  is  a  high
incidence  of  bone  growth
beyond  the  core  of  the  PEEK
spacer  and  cystic  regions
within  the  cage.  Given  our
experience,  we  currently
reserve  the  use  of  PEEK  and
rhBMP-2  for  use  in  those
patients  who  are  at  greatest
risk  of  pseudoarthrosis.
Included  PubMed
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
6 Annis, P.,
Brodke, D.S.,
Spiker, W.R.,
Daubs, M.D.,
Lawrence, B.D.
2015
The fate of L5-S1 with
low-dose BMP-2 and
pelvic ﬁxation, with or
without interbody fusion,
in adult deformity
surgery
Spine Retrospective review of 61
consecutive patients with
minimum 2-year follow-up at a
single institution. All patients
had an isolated posterior
approach, 5 or more  levels
fused including L5–S1, use of
pelvic ﬁxation, and no prior
L5-S1 procedures. The patients
were divided in 2 groups for
comparison on the basis of the
use of an interbody cage/fusion
at the L5–S1 level. Revision
rates and implant-related
complications were also
reported.
The fusion rate at L5–S1 was 97%
(59/61), with no difference between
the interbody and no interbody
fusion groups (97% vs. 96%, p = 1.0).
There were no signiﬁcant
differences in the radiographical
parameters or deformity correction
between the groups. The mean
amount of BMP-2 used in the
interbody group was 4.1 mg  (2–10),
2.5 mg  (0–8) in the disk space, and
1.6 mg  (0–4) in the interbody cage,
whereas there was no difference in
the amount of recombinant human
bone morphogenic protein-2 placed
posterolaterally between the
2 groups (interbody fusion = 1.6 vs.
non-interbody fusion = 2.0 mg,
p = 0.08) along with autograft and
allograft. The overall revision rate
for L5–S1 nonunion was 1.6%.
The use of low dose of
BMP-2 at the L5–S1 level
in combination with
sacropelvic ﬁxation
achieved satisfactory
fusion rates in adult
deformity surgery. No
additional beneﬁt was
encountered by adding
an interbody cage.
Included SCOPUS
7 Theologis, A.A.,
Tabaraee, E.,
Lin, T., Lubicky,
J., Diab, M.  2015
Type of bone graft or
substitute does not affect
outcome of spine fusion
with instrumentation for
adolescent idiopathic
scoliosis
Spine Children (10–18 yr) with AIS
who underwent deformity
correction via a posterior
approach were identiﬁed in the
Spinal Deformity Study Group
database. All had a minimum of
2-year follow-up. Patients were
subdivided into 3 groups based
on bone graft used: AIC,
allograft, and bone substitute
(BS). Clinical data included
patient demographics,
operative details, postoperative
analgesic use, and
perioperative complications.
Lenke curve type and curve
magnitude changes were
radiographically analyzed. The
Scoliosis Research Society-30
questionnaire was used to
assess clinical outcomes.
461 patients met  inclusion criteria
(girls: 381, boys: 80; average age
14.7 ± 1.7) and consisted of 152 AIC
patients (124 girls, 28 boys), 199
allograft patients (167 girls, 32 boys),
and  110 BS patients (90 girls, 20
boys). There was no difference in
age (p = 0.41) or gender (p = 0.82). The
BS group had signiﬁcantly smaller
preoperative curves and shorter
operative times. Postoperatively,
patients who  received BS had
signiﬁcantly longer hospital stays,
used higher quantities of
patient-controlled intravenous
analgesia and used epidurals
longer. The AIC group used
patient-controlled intravenous
analgesia signiﬁcantly longer. There
were no differences between the
groups in regards to curve type,
number of levels fused,
postoperative infections,
pseudarthrosis, reoperations for
any indication, and Scoliosis
Research Society-30 scores at the
latest follow-up.
Outcomes after primary
posterior spinal fusion
with instrumentation are
not inﬂuenced by type of
bone graft or substitute.
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
8 Quantitative study of
parathyroid hormone (1-34)
and bone morphogenetic
protein-2 on spinal fusion
outcomes in a rabbit model
of lumbar dorsolateral
intertransverse process
arthrodesis
Spine Forty-eight male New Zealand
white rabbits underwent bilateral
posterolateral intertransverse
process arthrodesis surgery at the
L5–L6 level. Animals were divided
into 6 groups. Two groups were
treated with autograft alone or
autograft and PTH (1-34), whereas
the other 4 groups were treated
with low-dose rhBMP-2 alone,
high-dose rhBMP-2 alone, or either
dose combined with PTH (1-34).
All animals were euthanized 6
weeks after surgery. The L4–L7
spinal segment was removed and
assessed using manual palpation,
computed tomography (CT), and
biomechanical testing.
CT assessments revealed fusion in
50% of autograft controls, 75% of
autograft PTH (1-34) animals, 87.5%
in the 2 groups treated with
low-dose rhBMP-2, and 100% in the
2 groups treated with high-dose
rhBMP-2. CT volumetric analysis
demonstrated that all groups
treated with biologics had fusion
masses that were on average
signiﬁcantly larger than those
observed in the control group
(p < 0.0001). Biomechanical data
demonstrated no statistical
difference between controls, PTH
(1-34), and low-dose rhBMP-2 in any
testing orientation. PTH (1-34) did
not increase bending stiffness when
used adjunctively with either
low-dose or high-dose rhBMP-2.
Although intermittent
teriparatide administration
results in increased fusion
mass volume, it does not
improve biomechnical
stiffness over use of
autograft alone. When
delivered concurrently with
high-and low-dose
rhBMP-2, teriparatide
provided no statistically
signiﬁcant improvement in
biomechanical stiffness.
Level of evidence: N/A
Included SCOPUS
9 Prospective, randomized,
controlled trial of
silicate-substituted calcium
phosphate versus rhBMP-2
in a minimally invasive
transforaminal lumbar
interbody fusion
Spine Fifty-two patients undergoing a
single-level unilateral MIS  TLIF
were evenly randomized into 2
cohorts as follows: the Actifuse
cohort received Actifuse combined
with 5 mL  of bone marrow aspirate
(n = 26; 50%), whereas the rhBMP
cohort received 4.2 mg of rhBMP-2
(n = 26; 50%). A pre hoc G*Power
analysis yielded a sample size of
n = 26 that was determined
through a 2-tailed distribution
calculation. Computed
tomographic analysis was
performed at 6 months and 1 year
postoperatively. Pre-and
postoperative visual analog scale
scores were obtained to assess the
clinical outcomes. Arthrodesis
was determined by 2 separate,
blinded orthopedic surgeons and a
board certiﬁed radiologist.
At 1-year follow-up, 65% (17/26) of
the Actifuse cohort and 92% (24/26)
of the rhBMP-2 cohort
demonstrated a radiographical
arthrodesis (p = 0.01). In both study
cohorts, the 1-year postoperative
visual analog scale scores
signiﬁcantly improved (p < 0.001).
Pseudarthrosis rates at 1 year were
35.0% (9/26) and 7.7% (2/26) for the
Actifuse and rhBMP-2 groups,
respectively (p = 0.01, OR = 6.35, 95%
CI = 1.22–33.1). A greater reoperation
rate was noted in the Actifuse
cohort (35.0%, 9/26) compared with
the BMP-2 cohort (7.7%, 2/26;
p = 0.01). One  patient with BMP-2
also experienced symptomatic
neuroforaminal bone growth (3.8%,
n = 1/26).
Silicate-substituted
calcium phosphate was
associated with a
signiﬁcantly lower rate of
arthrodesis than rhBMP-2
in a MIS  TLIF. The patients
with pseudarthrosis in
both cohorts were all
clinically symptomatic
with an unimproved visual
analog scale score.
Additional analysis of
Actifuse and other graft
enhancers/extenders are
needed prior to the
utilization for an MIS  TLIF
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
10 Complications of rhBMP-2
utilization for posterolateral
lumbar fusions requiring
reoperation: A single
practice, retrospective case
series report
Spine
Journal
Inclusion criteria were
posterolateral fusion with
rhBMP-2 implant and age
equal to or older than
18 years. Surgical
indications and treatment
were performed in
accordance with the
surgeon’s best knowledge,
discretion, and experience.
Patients consented to
lumbar decompression and
arthrodesis using rhBMP-2.
All  patients were educated
and informed of the
off-label utilization of
rhBMP-2. Patient follow-up
was performed at regular
intervals of 2 weeks,
6 weeks, 12 weeks, 6
months, 1 year, and later if
required or indicated.
Average age was 59.2 years,
and body mass index was
30.7 kg/mÂ. Numbers of levels
fused were 1 (414, 35.8%), 2
(469, 40.5%), 3 (162, 14.0%), 4
(70, 6.0%), 5 (19, 1.6%), 6 (11,
0.9%), 7 (7, 0.6%), 8 (4, 0.3%),
and 9 (2, 0.2%). Patients having
complications requiring
reoperation were 117 of 1158
(10.1%): symptomatic
nonunion requiring redo
fusion and instrumentation
41 (3.5%), seroma with acute
neural compression 32 (2.8%),
excess bone formation with
delayed neural compression
4  (0.3%), and infection
requiring debridement
26 (2.2%). Nonunion was
related to male sex and
previous BMP  exposure.
Seroma formation was
signiﬁcantly higher in patients
with higher doses of rhBMP-2
(p = .050) and with more  than
12 mg of rhBMP-2 (2 = 0.025).
Bone reformation and neural
compression at the
laminectomy and
foraminotomy sites occurred
in a delayed fashion. Infection
was associated with obesity
and respiratory disease.
Infections were noted with a
greater BMP  dose (p < .001),
more than 12 mg  (2 < 0.001),
fusion more  than three levels
(2 < 0.001), and reexposed to
BMP  (2 = 0.023).
rhBMP-2 utilization for
posterolateral lumbar
fusions has a low
symptomatic nonunion
rate. Prior rhBMP-2
exposure and male sex
were related to
symptomatic nonunion
formation.
rhBMP-2-associated neural
compression acutely with
seroma formation and
delayed with foraminal
bone formation is
concerning and associated
with higher rhBMP-2
concentrations.
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
11 Clinical sequelae after
rhBMP-2 use in a
minimally invasive
transforaminal lumbar
interbody fusion
Spine
Journal
A  retrospective review of 610
consecutive patients undergoing an
MIS-TLIF (2007–2010) by a single
surgeon at our institution was
performed (mean age 48.7 years,
range 26–82 years). All patients
underwent an MIS  laminectomy
with bilateral facetectomy, single
TLIF cage, unilateral pedicle screw
ﬁxation, and 12 mg (large kit) or
4.2 mg (small kit) of rhBMP-2. The
BMP-2 collagen-soaked sponge was
placed anteriorly in the disk space,
followed by local bone graft, and
then the cage was ﬁlled only with
local bone and no BMP-2. Patients
were evaluated at 6 months and 1
year with computed tomography
(CT) scan. Those demonstrating
neuroforaminal bone growth,
osteolysis/cage migration, or
pseudarthrosis were reviewed, and
cost data including direct
cost/procedure for both index and
revision surgeries were collected.
Of the 573 patients, 10 (1.7%)
underwent 15 additional
procedures based on recalcitrant
radiculopathy and CT  evidence of
neuroforaminal bone growth,
vertebral body osteolysis, and/or
cage migration. Thirty-nine
patients (6.8%) underwent
reoperation for clinically
symptomatic pseudarthrosis. Bone
overgrowth was associated with
nerve impingement and
radiculopathy in all 10 patients
(small kit, n = 9; large kit, n = 1).
Osteolysis and cage migration
occurred in 2 (20%) of these same
10 patients. Average total costs
were calculated per procedure
($19,224), and the costs for
reoperation equaled $14,785 per
encounter for neuroforaminal bone
growth and $20,267 for
pseudarthrosis.
Symptomatic ectopic bone
formation, vertebral
osteolysis, and
pseudarthrosis are
recognized complications
with the use  of rhBMP-2 in
MIS-TLIFs. Potential
causes include improper
dosage and  a closed space
that prevents the egress of
the postoperative BMP-2
ﬂuid collection.
Management of these
complications has a
substantial cost for the
patient and the surgeon
and needs to be
considered with the
off-label use of rhBMP-2.
Included SCOPUS
12 RhBMP-2 Is superior to
iliac crest bone graft for
long fusions to the
sacrum in adult spinal
deformity
Spine A total of 63 consecutive patients,
from 1997 to 2006, comprised of 31
patients in the BMP  group and 32
patients in the ICBG group, operated
on at a single institution with a
minimum 4-year follow-up (4–14 yr)
were analyzed. Inclusion criteria
were ambulators who  were
candidates for long fusions (thoracic
as the upper level) to the sacrum.
Exclusion criteria were revisions,
neuromuscular scoliosis, ankylosing
spondylitis, and patients who  had
both BMP  and ICBG used for fusion.
Oswestry Disability Index and 3
domains of the Scoliosis Research
Society score were used to assess
outcomes.
The 2 groups were similar with
respect to age, sex, smoking
history, comorbidities, BMI,
number of fusion levels and  Cobb
angles. Eight patients in the BMP
group underwent a posterior only,
whereas 23 underwent combined
anterior and posterior (A/P)
surgery. All 32 patients in the ICBG
had A/P  fusion. The average BMP
level was 11.1 mg (3–36 mg). The
rate pseudarthrosis was 6.4% (2/31)
in the BMP  and 28.1% (9/32) in the
ICBG group (p = 0.04) using Fisher
exact test and odds ratio = 5.67. The
fusion rates for BMP  group were
93.5% and 71.9% for the ICBG
group. Oswestry Disability Indexes
were similar between groups.
However, the BMP  group
demonstrated superior sum
composite Scoliosis Research
Society scores in pain, self-image
and function domains (p = 0.02).
BMP  is superior to ICBG in
achieving fusion in long
constructs in adult
deformity surgery. The
rate of pseudarthrosis was
signiﬁ cantly higher in the
ICBG group than BMP
group. The concentration
and dosage of
recombinant human bone
morphogenetic protein 2
(rhBMP-2) used seems to
have an effect on the rate
of fusion and
pseudarthrosis rate
because no patient
receiving more  than 5 mg
per level had apparent or
detected pseudarthroses
(n = 20/20).
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and  Year
Title  Journal  Sample  Main  ﬁndings  Conclusion  Reason  for
inclusion/
exclusion
Database
13  Fusion  rates  in  multilevel,
instrumented  anterior
cervical  fusion  for
degenerative  disease  with
and  without  the  use  of
bone  morphogenetic
protein
Journal  of
Neuro-
surgery:
Spine
The  authors  conducted  a
retrospective  cohort  study  of
patients  who  underwent
multilevel  (2+  level)  anterior
cervical  fusions  performed  for
degenerative  disk  disease  with  or
without  the  concurrent  use  of
BMP-2  from  1997  to  2012.  The
dosage  throughout  the  study
ranged  from  2.1  to  0.26  mg/level
(mean  1.0  mg/level).  All  patients
were  evaluated  postoperatively  by
means  of  radiographs  and  CT
scans  to  determine  fusion  status.
The  overall  fusion  rate  for  the
patients  treated  without  BMP  (n  =  23)
was  82.6%  compared  with  a  100%
fusion  rate  in  the  group  treated  with
BMP  (n  =  22)  (p  =  0.04).  The
pseudarthrosis  rates  increased  with
number  of  fusion  levels  in  patients
who  did  not  receive  BMP,  whereas  all
patients  in  the  group  treated  with
BMP  had  solid  arthrodesis.
Furthermore,  there  were  2
instrumentation  failures  in  the
non-BMP  group.  There  was  a  direct
correlation  between  the  incidence  of
complications  and  the  dosage  of  BMP
used  per  level,  with  no  complications
reported  at  doses  equal  to  or  less
than  1.1  mg/level.
The  overall  rate  of  bony
arthrodesis  was  increased
following  the  use  of  BMP
in  multilevel  anterior
cervical  fusion.  Traditional
methods  without  BMP  had
a  high  rate  of
pseudarthrosis.  The
complications  associated
with  the  use  of  BMP
appeared  to  be  dose
related  and  of  low
incidence  when  BMP  is
used  in  doses  equal  to  or
less  than  1.1  mg/level.
Included  SCOPUS
14  Multilevel  anterior  cervical
discectomy  and  fusion
with  and  without  rhBMP-2:
A  comparison  of  dysphagia
rates  and  outcomes  in  150
patients  -  Clinical  article
Journal  of
Neuro-
surgery:
Spine
The  authors  retrospectively
reviewed  150  patient  records.
Group  1  (BMP  group)  consisted  of
100  patients  who  underwent
multilevel  ACDF  with  PEEK  cages
ﬁlled  with  rhBMP-2  and
instrumented  with  a  cervical
plate.  Group  2  (allograft  group)
included  a  matched  control
cohort  of  50  patients  who
underwent  multilevel  ACDF  with
allograft  spacers  and  anterior
plate  ﬁxation  (without  rhBMP-2).
Patient  demographics  were  not
signiﬁcantly  different  between
the  groups.  Fusion  was  assessed
by  means  of  dynamic  radiographs
and/or  CT  at  routine  intervals.
Complications,  dysphagia
incidence,  standardized
dysphagia  score,  Nurick  grades,
and  fusion  rates  were  assessed.
The  mean  follow-up  for  the  BMP
group  (Group  1)  was  35  months  while
the  mean  follow-up  for  the  allograft
group  (Group  2)  was  25  months.
There  was  a  complication  rate  of  13%
in  the  BMP  group  compared  with  8%
in  the  allograft  group  (p  <  0.005).
There  was  no  signiﬁcant  difference  in
overall  dysphagia  incidence  between
the  BMP  group  and  the  allograft
group  (40%  vs  44%,  respectively;
p  >  0.05).  However,  there  was  a
signiﬁcant  difference  in  the  severity
of  dysphagia  (using  the  SWAL-QOL
dysphagia  scoring  system)  between
the  2  groups:  0.757  for  the  BMP  group
versus  0.596  for  the  allograft  group
(p  <  0.005).  In  subgroup  analysis,  the
use  of  rhBMP-2  signiﬁcantly
increased  the  severity  of  dysphagia  in
patients  undergoing  2-level  ACDF
(p  <  0.005).  However,  the  severity  of
dysphagia  did  not  differ  signiﬁcantly
between  groups  when  3-  or  4-level
ACDF  cases  were  compared.  There
was  no  pseudarthrosis  in  Group  1
(the  BMP  group)  compared  with  a  16%
pseudarthrosis  rate  in  Group  2  (the
allograft  group)  (p  <  0.05).  There  was  a
weak  correlation  between  the  total
rhBMP-2  dose  and  the  dysphagia
score  (Kendall  tau  rank  correlation
coefﬁcient  0.166,  p  =  0.046).
The  use  of  rhBMP-2  in
patients  undergoing
2-level  ACDF  signiﬁcantly
increases  the  severity  of
dysphagia  (dysphagia
score)  without  affecting
the  overall  incidence  of
dysphagia.  However,  there
is  no  statistically
signiﬁcant  difference  in
the  incidence  or  severity  of
dysphagia  between
patients  undergoing
3-level  or  4-level  ACDF
treated  with  PEEK/rhBMP-2
and  those  treated  with
only  allograft.  The  use  of
rhBMP-2  appears  to  reduce
the  risk  of  pseudarthrosis.
This  beneﬁt  is  most
pronounced  in  patients
who  undergo  4-level  ACDF
and  are  smokers.
Included  SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
15 Nanocomposite therapy
as a more  efﬁcacious
and less inﬂammatory
alternative to bone
morphogenetic
protein-2 in a rodent
arthrodesis model
Source of the
Document
Journal of
Orthopedic
Research
This study evaluates a
combination therapy
(TrioMatrix®; Pioneer Surgical,
Inc., Marquette, MI)  comprised of
a demineralized bone matrix
(DBM), hydroxyapatite, and a
nanoﬁber-based collagen scaffold
in a rodent spine fusion model.
Thirty-six athymic rats that
underwent a posterolateral
intertransverse spinal fusion
were randomly assigned to 1 of 5
treatment groups: absorbable
collagen sponge alone (ACS,
negative control), 10 g rhBMP-2
on ACS (positive control),
TrioMatrix®, Grafton® (Osteotech,
Inc., Eatontown, NJ), and DBX®
(Synthes, Inc., West Chester, PA).
Both TrioMatrix® and
rhBMP-2-treated animals
demonstrated 100% fusion rates as
graded by manual palpation scores 8
weeks after implantation. This rate
was signiﬁcantly greater than those
of the ACS, Grafton®, and  DBX®
groups. Notably, the use of
TrioMatrix® as evaluated by microCT
quantiﬁcation led to a greater fusion
mass volume when compared to all
other groups, including the rhBMP-2
group. T2-weighted axial MRI  images
of the fusion bed demonstrated a
signiﬁcant host response associated
with a large ﬂuid collection with the
use of rhBMP-2; this response was
signiﬁcantly reduced with the use  of
TrioMatrix®.
Our  results therefore
demonstrate that a
nanocomposite therapy
represents a promising,
cost-effective bone graft
substitute that could be
useful in spine fusions
where BMP-2 is
contraindicated.
Included SCOPUS
16 Long-term outcomes of
revision fusion for
lumbar pseudarthrosis:
Clinical article
Journal of
Neurosurgery:
Spine
. This is a retrospective study of
47 patients who  underwent
revision lumbar arthrodesis for
pseudarthrosis-associated back
pain. Baseline 2-year outcomes
were assessed using the
following: visual analog scale
(VAS) for back pain, Oswestry
Disability Index (ODI), Zung
Self-Rating Depression Scale,
time to narcotic independence,
time to return to work, EuroQol
health-state utility, and physical
and mental quality of life (Short
Form [SF]-12 Physical and Mental
Component Summary scores).
The mean duration of time between
prior fusion and development of
symptomatic pseudarthrosis was
2.69 years. Bone morphogenetic
protein was used in 4 cases (8.5%) of
revision arthrodesis. A signiﬁcant
improvement in VAS back pain
(7.31 ± 0.81 vs. 5.06 ± 2.64, p = 0.001),
ODI  (29.74 ± 5.35 vs. 25.42 ± 6.0,
p = 0.001), and physical health SF-12
(23.83 ± 6.89 vs. 27.85 ± 8.90, p = 0.001)
scores was observed when
comparing baseline and 2-year
post-revision arthrodesis scores,
respectively, with a mean cumulative
2-year gain of 0.35 quality-adjusted
life years. The median time to
narcotics independence was 12.16
(interquartile range 1.5–24.0) months
and the median time to return to
work was 4 months (interquartile
range 3–5 months). By 2 years after
revision surgery, no patients had
experienced pseudarthrosis. The
SF-12 Mental Component Summary
(44.72 ± 7.90 vs. 43.46 ± 7.51, p = 0.43)
and Zung Self-Rating Depression
Scale scores (39.36 ± 7.48 vs.
41.39 ± 10.72, p = 0.37) were not
signiﬁcantly improved by 2 years
The  authors’ study
suggests that revision
lumbar arthrodesis for
symptomatic
pseudarthrosis provides
improvement in low-back
pain, disability, and quality
of life. Revision lumbar
arthrodesis should be
considered a viable
treatment option for
patients with
pseudarthrosis-related
back pain. Mental health
symptoms from
pseudarthrosis-associated
back pain may be more
refractory to revision
surgery.
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
17 Promoting fusion in
minimally invasive
lumbar interbody
stabilization with
low-dose bone
morphogenic protein-2 -
But what is the cost?
Spine
Journal
Study design: Prospective observational
study of consecutive patients
undergoing minimally invasive lumbar
interbody fusion with percutaneous
pedicle screws. Patient sample: Thirty
patients aged between 22 and 78 years
(mean 53 years). Outcome measures:
Thin-slice lumbar computed
tomography scanning with multiplanar
reconstruction at 6 and 12 months
postoperative. Methods: Thirty-six
spinal levels were instrumented in total,
of which four underwent posterior
lumbar interbody fusion and 32
underwent transforaminal lumbar
interbody fusion. Bone graft harvested
locally was placed in the disk space with
low-dose BMP-2 (1.4 mg  per level).
Thirty-three of 36 spinal levels
showed complete fusion at a
mean postoperative scan time of
7.1 months. Two levels
demonstrated partial fusion at 6
months, which was complete at
12 months. There was one case of
nonunion at 12 months, which
also demonstrated vertebral body
osteolysis. Despite very low-dose
BMP-2, two cases of
asymptomatic heterotopic
ossiﬁcation were observed, and
there were two cases of
perineural cyst formation, one of
whom required revision of the
interbody cage.
The use of BMP  with
autograft in the disk
space during minimally
invasive lumbar
interbody fusion is
associated with a high
rate of early fusion. Even
with very low-dose BMP
used in this study,
complications related to
BMP  usage were not
avoided completely.
Included SCOPUS
18 Bone Morphogenetic
Protein (RhBMP-2) as a
substitute for iliac crest
bone graft in multilevel
adult spinal deformity
surgery: Minimum
two-year evaluation of
fusion
Spine Prospective analysis was performed for
98 patients (308 levels; mean age, 51.4
years) who  underwent multilevel
anterior or posterior spinal fusion (PSF)
with minimum 2-year follow-up
(average, 2.6 years). Group 1 (10 mg/level)
contained 47 patients (109 levels; 2.33
levels/patient) who  underwent anterior
spinal fusion (ASF): BMP  on an
absorbable collagen sponge (ACS) with a
titanium mesh cage. Group 2
(20 mg/level) included 43 patients (156
levels; 3.63 levels/patient) with PSF: BMP
on an ACS with local bone graft (LBG)
and bulking agent [tricalcium
phosphate/hydroxyapatite (TCP-HA)].
Group 3 (40 mg/level) contained 8
patients (43 levels; 5.38 levels/patient)
with PSF: rhBMP-2 and TCP-HA with no
autologous bone. Confounding negative
factors were present in the study
population: medical comorbidities (26%),
tobacco use (17%), revision surgery
(34%), previous laminectomy (51%), and
preoperative pseudarthrosis (27%).
Postoperative ﬁlms (AP, lateral, oblique)
were evaluated by independent
observers. Average fusion grade was
based on a published scale.
Overall fusion rate was 95%.
(group 1 91%, group 2 97%, group
3 100%). No confounding factor
demonstrated a detrimental
statistical signiﬁcance to fusion.
In multilevel ASF,  BMP
(10 mg/level) generates
fusion without
autogenous bone. In
multilevel PSF, BMP
(20 mg/level) with LBG
and TCP-HA produced
fusion. BMP  (40 mg/level)
and TCP-HA without
LBG achieved fusion. In
multilevel spinal fusion,
rhBMP-2 eliminated the
necessity for iliac crest
bone graft and yielded
an excellent fusion rate.
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and Year
Title Journal Sample Main ﬁndings Conclusion Reason for
inclusion/
exclusion
Database
19 Prospective
nonrandomized
comparison of an
allograft with bone
morphogenic protein
versus an iliac-crest
autograft in anterior
cervical discectomy
and fusion
Spine
Journal
Purpose: The objective of this pilot
study was to compare the success of
BMP  combined with bone allograft
with iliac bone autograft in ACDF
patients. Study design/setting: The
institutional review board approved a
prospective but nonrandomized study
of 66 consecutive patients who  had
primary one- to three-level ACDF with
either iliac-crest bone autograft or BMP
allograft (0.9 mg BMP  per level)
followed prospectively over a 2- to
3-year period. Patient sample:
Consecutive patients who  had primary
one- to three-level ACDF with either
iliac-crest bone autograft (n = 36) or
BMP-allograft (n = 30). Patients in both
iliac bone graft and BMP-allograft
groups had comparable preoperative
pain and disability. Outcome
measures: Visual analog scale pain,
pain drawing, Oswestry index, pain
medication use, opinion of treatment
success, and neurological recovery.
Given the nonrandomized nature
of the study, the study groups were
not matched. Within this
limitation, both groups of patients
had similar improvement in all
outcome scales (visual analog scale
pain, pain drawing, Oswestry
index, pain medication use, and
opinion of treatment success) and
neurological recovery over the 2- to
3-year follow-up period. Patients in
the iliac bone graft group had  two
pseudarthroses and two
complications of the iliac-crest
donor site. In the BMP-allograft
group, one patient had a
pseudarthrosis, but 50% had neck
swelling presenting as dysphagia,
which was substantially more
common than the 14% present in
the iliac bone graft group. Patients
in the BMP-allograft group had
slightly shorter surgery time, but
implant and hospitalization costs
were higher.
ACDF performed with
BMP  (0.9 mg BMP  per
level) allograft is as
effective as iliac bone
graft in terms of patient
outcomes and fusion
rates. Safety concerns
related to neck swelling
and higher initial costs
were associated with
patients in the bone
morphogenic protein
group.
Included SCOPUS
20 Bone morphogenetic
protein-2 (BMP-2) in the
treatment of pyogenic
vertebral osteomyelitis
Spine Between 2003 and 2005, 14 patients
who underwent circumferential fusion
for PVO were included in this study.
Average patient age was 54 years
(range, 27–77 years). Eight (57%)
patients had 3 or more  vertebral
bodies involved. Diagnostic studies
included radiographs, CT, MRI, and
markers of infection [(C-reactive
protein (CRP), erythrocyte
sedimentation rate (ESR), white blood
count (WBC)]. All patients underwent
anterior fusion with rhBMP-2 inserted
in structural allograft (11 patients) or
titanium cylindrical cages (3 patients),
followed by posterior instrumented
fusion with autogenous iliac crest graft
(8 occurring on the same day).
Follow-up averaged 22 months (range,
11–30 months). All were studied with
plain radiographs, including
ﬂexion-extension lateral ﬁlms and ﬁne
cut CT scans with reconstruction. Pain
ratings were recorded by visual analog
scores (VAS).
Clinical resolution of infections,
normalization of lab values, and
bony fusion, based on dynamic
radiographs and CT scans, were
seen in all patients at latest
follow-up. Staphylococcus aureus
was the most frequently identiﬁed
organism (8 patients). Four (29%)
patients had positive blood
cultures (all MRSA). Predisposing
comorbidities were present in 12
patients. Six patients had epidural
abscesses. Eight (57%) patients
presented with neurologic deﬁcits,
ranging from paraparesis to
quadriplegia. Complete recovery
was seen in 7 (quadriplegia
unchanged). At 1 year, mean VAS
pain scores improved signiﬁcantly
(p < 0.05) from 7.9 (range, 3–10) to
2.8 (range, 0–6). Perioperative
complications (non-BMP related)
occurred in 2 patients. There were
no surgically-related deaths.
rhBMP-2 use, in
combination with
antibiotics and
circumferential
instrumented fusion,
provides a safe and
successful surgical
treatment of medically
nonresponsive PVO,
with solid fusions
obtained, good clinical
results, and  no adverse
side effects from the
BMP.
Included SCOPUS
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Table 1 – (Continued)
n.◦ Authors
and  Year
Title Journal Sample  Main  ﬁndings  Conclusion  Reason  for
inclusion/
exclusion
Database
21  Use  of  osteogenic
protein-1  in  patients
at high  risk  for  spinal
pseudarthrosis:  A
prospective  cohort
study  assessing
safety,  health-related
quality  of  life,  and
radiographic  fusion
Journal  of
Neuro-
surgery:
Spine
Outcome  measures  included
documentation  of  adverse  events,
radiographic  evaluation  of  fusion  by  an
independent  musculoskeletal
radiologist  blinded  to  treatment,  the
Oswestry  Disability  Index  (ODI),  and
the  36-Item  Short  Form  Health  Survey
(SF-36).  The  health-related  quality  of
life  (HRQOL)  assessments  (ODI  and
SF-36)  were  given  at  baseline  and  at  3,
6,  12,  18,  and  24  months  after  the
surgical  OP-1  implant.
The  study  consisted  of  17  male  and  13
female  patients,  with  a  mean  age  of  53  years
(range  20–77  years).  Fourteen  patients
underwent  operations  for  cervical  disease,
and  16  for  lumbar  disease,  with  a  median
postoperative  follow-up  of  24  months  (range
13–46  months).  There  were  signiﬁcant
improvements  in  the  physical  health  (from
28.7  ±  1.5  to  34.2  ±  3;  p  =  0.025)  and  mental
health  (from  43.7  ±  2  to  47.5  ±  3.1;  p  =  0.015)
summary  scores  on  the  SF-36.  The  mean
postoperative  ODI  score  at  6,  9,  12,  and  18
months  was  signiﬁcantly  lower  than  the
baseline  ODI  score,  after  taking  into
consideration  a  10-point  measurement  error
(p  =  0.0003,  p  =  0.003,  p  =  0.004,  and  p  =  0.032,
respectively).  At  24  months,  however,  the
differences  in  ODI  scores  were  no  longer
signiﬁcant.  Of  the  30  patients,  24  (80%)  were
deemed  to  have  a  solid  fusion.  There  were
no  allergic  reactions  to  OP-1  and  no
symptomatic  postoperative  hematomas.
Our  results  suggest  that
the  use  of  OP-1  is  safe
and  may  contribute  to
high  fusion  rates,  as
demonstrated  by
radiographs,  reduced
levels  of  disability,  and
improved  HRQOL  in
patients  considered  to
be  at  a  high  risk  for
developing  a  nonunion
after  spinal
reconstructive  surgery.
Included  SCOPUS
22  rhBMP-2  (ACS  and
CRM  formulations)
overcomes
pseudarthrosis  in  a
New  Zealand  white
rabbit  posterolateral
fusion  model
Spine  Seventy-two  New  Zealand  white
rabbits  underwent  posterolateral
lumbar  fusion  with  iliac  crest  autograft.
To  establish  pseudarthroses,  nicotine
was  administered  to  all  animals.  At  5
weeks,  the  spines  were  explored  and  all
pseudarthroses  were  redecorticated
and  implanted  with  no  graft,  autograft,
rhBMP-2/ACS,  or  rhBMP-2/CRM.  At  10
weeks,  fusions  were  assessed  by
manual  palpation  and  histology.
Eight  rabbits  (11%)  were  lost  to
complications.  At  5  weeks,  66  (97%)  had
pseudarthroses.  At  10  weeks,  attempted
pseudarthrosis  repairs  were  fused  in  1  of  16
of no  graft  rabbits  (6%),  5  of  17  autograft
rabbits  (29%),  and  31  of  31  rhBMP-2  rabbits
(with  ACS  or  CRM)  (100%).  Histologic  analysis
demonstrated  more  mature  bone  formation
in  the  rhBMP-2  groups.
The  2  rhBMP-2
formulations  led  to
signiﬁcantly  higher
fusion  rates  and
histologic  bone
formation  than  no  graft
and  autograft  controls
in  this  pseudarthrosis
repair  model.
Included  SCOPUS
23  Osteogenic  protein-1
induced  gene
expression:
Evaluation  in  a
posterolateral  spinal
pseudarthrosis
model
Spine  Messenger  ribonucleic  acid  was
isolated  from  nicotine-exposed  New
Zealand  white  rabbit  lumbar
pseudarthroses  following  attempted  no
graft,  autograft,  and  osteogenic
protein-1  pseudarthrosis  repairs.
Reverse  transcriptase  polymerase
chain  reaction  was  used  to  assess  the
expression  of  angiogenin,  angiopoietin,
intercellular  adhesion  molecule,
platelet-derived  growth  factor-,
vascular  endothelial  growth  factor,
bone  morphogenetic  proteins  2  and  7,
type  I  collagen,  and  osteonectin.
Glyceraldehyde-3-phosphate
dehydrogenase  was  used  as  a
constitutively  expressed  control.
Levels  of  gene  expression  in  the  osteogenic
protein-1  group  were  higher  than  those  of
the  autograft  group,  which  were  higher  than
the  no  graft  group  for  the  majority  of  the
genes  studied.
In  the  rabbit
pseudarthrosis  model,
gene  expression  data
supported  the
hypothesis  that
successful
pseudarthrosis  repair  is
related  to  the  induction
of  osteogenic  and
angiogenic  cytokines  by
osteogenic  protein-1.
Included  SCOPUS
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(approved for anterior lumbar interbody fusions – ALIF) and
rhBMP-7 (has received a humanitarian device exemption
approval for repair of lumbar pseudarthrosis).4,5
By July of 2002, the FDA approved the use of rhBMP-2 com-
bined with a biologic carrier of collagen (bovine type I collagen)
as a substitute for single level ALIF.1,2,6–8 According to Nadyala
et al.9 the rhBMPs are currently the most effective osteobio-
logic agents to increase the rate of arthrodesis but are often
used as an off label application. Mulconrey et al.1 describes
sustainable results of success, by multiple centers, demon-
strating to be superior to ICBG for ALIF. Its use had a rapidly
increasing in the United States, despite the initial high costs.7
The study of Klimo et al.10 has demonstrated that the
fusion process using rhBMP-2 is a dynamic one, with osteolysis
dominating the initial phase, leading to end-plate resorption
and consequently loss of some of the disk space height and
sagittal alignment that was achieved with surgery. The rhBMP-
7 has been documented as a potential treatment alternative
for different diseases, including bone disease, stroke, inﬂam-
matory bowel disease, prostate cancer, and chronic renal
disease.4 More  explicitly, rhBMP-7 plays an important role
in bone formation by inducing differentiation of pluripotent
mesenchymal cells into active osteoblasts, Furlan et al.4 con-
cludes that it can induce a stable, mature, posterolateral spinal
fusion mass more  rapidly than an autologous bone graft, and
the resulting fusion mass may be biomechanically stiffer in
the early stages (up to 3 months) of healing.
BMP  had a 98% vs. ICBG 76% of fusion rate, once been
extended its use to off label posterior spinal fusion, ante-
rior/posterior cervical fusion. To Mulconrey et al.1 at a single
level research of 2 years, BMP  demonstrate a superior pos-
terolateral spinal fusion rate (88%) than ICBG (73%). Those
patients had decreased blood loss, shorter length of surgery
and shorter hospital stay.1,11 According to Hoffmann et al.7
rhBMP-2 is more  effective with a reduction in radiographic
nonunion compared with BMP-7, demineralized bone matrix,
and activated growth factor.
It must be evaluated all the variables in the spinal fusion,
the detrimental factors to fusion are medical comorbidi-
ties, tobacco use, preoperative pseudarthrosis, preoperative
laminectomy, age, increasing number of surgical levels. Oth-
ers are osteoporosis, minimal local bone graft, previous and
long fusion.1 Failures have been attributed to poor vascularity
of a scarred fusion bed and persistence of systemic inhibitors,
such as nicotine.5 To Furlan et al.4 the population at risk for
a spinal nonunion are patients with connective tissue disor-
ders, individuals with a history of major diseases that could
adversely affect bone healing, patients receiving medications
that negatively affect bone healing, patients with a history
of previous nonunion fusions, and/or patients with limited
availability or poor quality of autogenous bone graft.
Singh et al.6 and Hsu et al.12 emphasizes that applying
BMP  is not without risk, the FDA in 2008 issued a public
health warning to its use in cervical spine fusion alert-
ing to wound complications, dysphonia, dysphagia and
ectopic bone formation. In the lumbar spine, reports have
demonstrated radiculitis, pseudarthrosis, seroma/hematomaPlease cite this article in press as: Oliveira OR, et al. The use of bone morp
Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.03.005
formation, and heterotopic ossiﬁcation with rhBMP-2 use.
Apprehension about its pro-oncogenic potential has limited
its use in the pediatric population, although this trend may;x x x(x x):xxx–xxx
be changing.2,7,12 Both Singh et al.6 and Hoffmann et al.7
groups theorizes that the lack of postoperative dead space
in Minimally invasive transforaminal lumbar interbody
fusion (MIS-TLIFs) surgery may lead to an inﬂammatory
state because of the high concentration of BMP-2, resulting
in edema and seroma, theoretically inducing radiculitis,
vertebral osteolysis and neuroforaminal bone growth.6,7
Pyogenic vertebral osteomyelitis is one of less common
complications after spinal fusion, present late or in patients
with multiple medical morbidities such as diabetes, HIV or
rheumatoid conditions; the use of BMPs to correct this hostile
environment of pyogenic infection it is proven effective man-
aged by circumferential instrumented fusion in combination
with antibiotics, according to Allen et al.13 it has good evidence
of bony fusion, no infection recurrence and the patients had
clinical improvement.
Hoffmann et al.7 afﬁrms that there is no signiﬁcant authen-
tic immunologic antibody response to rhBMP-2 or type I bovine
collagen, and the reexposure does not lead to a symptomatic
antibody formation according to serology testing.
Pseudoarthrosis occur when the fusion attempt fails, a
solid fusion is not achieved, or there is motion across the
segment leading to it, and it can be clinically symptomatic as
pain, deformity, neurocompression or hardware failure. The
risks factors are: osteoporosis, cervical kyphotic deformity,
revision fusion surgery, multilevel surgery, or a history of
smoking.11 Adogwa et al.14 suggests that revision surgery
of lumbar arthrodesis for symptomatic pseudarthrosis is a
viable treatment that improves low-back pain, disability and
quality of life. Pseudarthrosis after spine fusion leads to poor
clinical outcomes and a signiﬁcant cost to patients and the
healthcare system.12
The study of Lu et al.11 says it is interesting to note that
a majority (63%) of the allograft cohort patients who  exhib-
ited pseudarthrosis were smokers, whereas all the patients
who were in the BMP group had a solid fusion regardless of
smoking status. The use of rhBMP-2 appears to reduce the
risk of pseudarthrosis, but this beneﬁt is most pronounced
in patients treated with 4-level anterior cervical discectomy
fusion (ACDF) who are smokers.
Pseudoarthrosis is one of the most common complications
after long adult spinal fusion to the sacrum and typically
occurs at the thoracolumbar and lumbosacral junctions.15
Is a major limitation of multilevel anterior cervical fusion,
traditional techniques have a 20% of patients who develop
pseudarthrosis, one strategy used to help decrease the rate
of it is to have posterior instrumentation to increase the rigid-
ity of the construct, however it adds morbidity by increase the
time of surgery. Frenkel et al.16 demonstrate that BMP  usage
in anterior cervical approach has almost 100% rate of solid
arthrodesis regardless of level, but its study does not have
statistical signiﬁcance.
According to Singh et al.6 6.8% of patients who underwent
a MIS-TLIF procedure were identiﬁed as having pseudarthro-
sis, they all were clinically symptomatic and underwent a
revision arthrodesis – a contralateral MIS-TLIF. Patients with
revision surgery because of pseudarthrosis are younger thanhogenetic proteins (BMP) and pseudarthrosis, a literature review. Rev
those who did not have a revision (p < .001), it is a group of
patients with a high prevalence of smokers compared with
the ones who did not need revision (41.3% vs. 26.7%, p < .054).
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he need for review procedure for those patients costs an aver-
ge of $20,267 (American dollars) of hospital direct costs and
hysician charges.
Pseudarthrosis at L5–S1 is one of the most common com-
lications of long fusions to the sacrum in adult deformity
urgery. Strategies for decreasing it include interbody fusion,
se of BMP-2 at the lumbosacral junction, and the use of sacro-
elvic ﬁxation, individually or in combination.17 The repair in
he lumbar spine presents a challenging surgical problem with
igh failure rates been reported, resulting from poor vascular-
ty in a scarred fusion bed, inadequate posterior bony surface
rea, loss of sagittal alignment, and exposure to adverse sys-
emic factors such as nicotine. Higher fusion rates were noted
ith rhBMP-7 than autograft in this setting (82% vs. 42%)
n those cases. Another potential bone graft alternative that
as been extensively studied is rhBMP-2, demonstrated by
awrence et al.18 to overcome the inhibitory effects of nico-
ine in a model of primary spinal fusion and appears to be an
ffective alternative in its preclinical model for a scenario with
nnumerous risk factors for pseudarthrosis repair.
Future studies should be conducted to elucidate the under-
ying control over the observed gene expression involved
n pseudarthrosis, the expression of certain osteogenic and
ngiogenic genes that have been previously demonstrated to
e inhibited by nicotine. For the White et al.5 model it had
p-regulation in the implantation of osteogenic protein-1 at
he pseudarthrosis site. Gene expression data supported the
ypothesis that the discrepancy in fusion success may be due
o osteogenic protein-1’s ability to up-regulate osteogenic and
ngiogenic cytokines required for fusion, and, thus, overcome
icotine’s inhibition of local gene expression.
According to Mulconrey et al.1 rhBMP-2 has the ability
o create solid fusion in the presence of negative variables
nd in multilevel spinal fusion, eliminating the necessity for
liac crest bone graft, to Hoffmann et al.7 non-union rates
n lumbar spine fusion with rhBMP-2 are low, a high dosage
>12 mg)  is associated with higher chance of postoperative
eroma and infection requiring invasive intervention, such as
eutilization of it.
Frenkel et al.16 indicates that cervical fusion approach with
MP  its possible without increase in complication rates if
sing lower doses of BMP,  following the safety concern of the
DA notiﬁcation, any multilevel anterior cervical procedure,
ven without BMP,  can lead to dysphagia and airway problems.
lthough according to Lu et al.11 the use of rhBMP-2 in patients
ndergoing 2-level ACDF signiﬁcantly increases the severity of
ysphagia, without affecting the overall incidence of it. MIS-
LIFs showed neural compromise by a case series evaluated,1
lthough rmBMP-2 is effective for arthrodesis in the unilateral
IS-TLIF the complication of this off-label usage are present –
euroforaminal bone growth, osteolysis and pseudarthrosis.6
Kim et al.15 conﬁrms that BMP  is superior to ICBG in
chieving fusion in long constructs in adult deformity surgery.
he rate of pseudarthrosis was signiﬁcantly higher in the
CBG group than BMP  group, the concentration and dosage of
hBMP-2 used seems to have an effect on the rate of fusion
nd pseudarthrosis rate because no patient receiving morePlease cite this article in press as: Oliveira OR, et al. The use of bone morp
Bras Ortop. 2016. http://dx.doi.org/10.1016/j.rboe.2016.03.005
han 5 mg  per level had apparent or detected pseudarthrosis
n = 20/20). x x(x x):xxx–xxx 15
To Buttermann19 (2008) BMP seems to have greater indica-
tion in patients having three- or greater-level ACDF, patients
who are undergoing revision, patients who have morbid obe-
sity or diabetics and are at risk of bone graft site complications,
and patients who have osteoporosis in which the iliac-crest
bone graft itself may be subject to collapse or exhibits a risk
of subsidence.
Veillete and McKee8 agree that for lumbar spine fusion the
use of BMP showed an increased fusion rate, with a decrease
of revision procedures in the same period, but it has no corre-
lation with decrease in the use of ICBG and the use of BMP
correlates with substantial increase in hospital chargers. It
may question ﬁnancial justiﬁcation. Kim et al.15 justify that
for long fusions to the sacrum BMP use signiﬁcantly decreases
pseudarthrosis rates in this patient population when com-
pared with ICBG alone. Witch corroborates with Annis et al.17
study where the use of low dose of BMP-2 at the L5–S1 level in
combination with sacro-pelvic ﬁxation achieved satisfactory
fusion rates in adult deformity surgery.
Currently, most of the burden of the increased costs is
borne by the hospitals and surgeon providers. However, over
the long term, the costs may be similar and have yet to be
determined conclusively.19 The future market for BMP-2 in
lumbar fusion surgery will depend on the clinical signiﬁcance
of increased fusion in the context of possible side effects and
cost considerations, as well as the potential arrival of newer
and safer fusion-promoting agents.20 To Frenkel et al.16 the
BMP-group has a faster fusion progress in a 3-month follow-up
than in non-BMP group.
The efﬁcacy of TLIF with BMP is supported in the large
series with long-term follow-up of Crandal et al.21 Reliable
fusion and improved outcomes can be expected in adults
undergoing TLIF for deformity, spondylolisthesis, and degen-
erative disease. Most complications occurred in patients with
deformity.
Furlan et al.4 results suggest that the use of rhBMP-7 is safe
and may contribute to high fusion rates, as demonstrated by
radiographs, reduced levels of disability, and improved quality
of life in patients considered to be at a high risk for developing
a nonunion after spinal reconstructive surgery. At Theologis
et al.22 study shows no difference in outcomes between autog-
enous iliac crest, allogeneic bone graft, and bone substitutes in
primary posterior spine fusion with instrumentation in idio-
pathic scoliosis. This study contributes to the growing body of
evidence that rhBMP-7 is safe for surgical use in the clinical
arena. The use of an rhBMP-7 implant may be a contributing
factor to the elevated rate of radiographic fusion, improved
quality of life, and reduced degree of disability after spinal
fusion that was observed in its group of patients at a high risk
for developing pseudarthrosis. It does not confer additional
beneﬁt when bone fusion is likely to occur in a normal fashion;
however, in patients with one or more  risk factors for impaired
bone healing, the adjuvant use of it may negate these effects,
allowing adequate bone fusion to occur.
Crandall et al.23 ﬁve-year follow-up after TLIF with BMP,
conﬁrms effective arthrodesis in short and long fusions, both
primary and revision surgeries. Most complications occurredhogenetic proteins (BMP) and pseudarthrosis, a literature review. Rev
in deformity patients, the BMP-related ones (seroma, ectopic
bone) were rare.
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Even with very low dose BMP  used in the study of Mannion
et al.20 complications related to BMP  usage were not avoided
completely, it was observed asymptomatic heterotopic ossi-
ﬁcation and two cases of perineural cyst formation, one of
whom required revision. Hoffmann et al.7 points out the need
of additional research to determine dose dependency and
genetic predisposition to react to BMPs, such as over (ectopic
bone and seroma) or underreaction (nonunion).
Final  remarks
Our review shows that the use of BMPs is effective and secure
compared to ICGB, but depending of the location of usage (cer-
vical spine, lumbar spine or sacrum) and the medical status of
the patient (presence of comorbidities, tobacco usage) its more
probable to exhibit complications, such as neuroforaminal
bone growth, osteolysis, pseudarthrosis, seroma, hematoma.
This data determine that the usage of BMPs must be an agree-
ment between patient and physician, an informed decision
discussing the beneﬁts and risks of BMP  for each case.
Conﬂicts  of  interest
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